The Joint, headquartered in Scottsdale, Arizona, operates approximately 135 corporate clinics and 800 franchises, employing 444 staff. The company went public on November 11, 2014, offering wellness packages and digital record management.
Based on our analysis, Joint has received an overvalued rating of 1 out of 5 stars from Cashu. Several key financial ratios indicate that the company is currently not performing well compared to its sector peers, which raises concerns about its valuation.
One notable metric is the Price-to-Book (PB) Ratio, which stands at 9.37. This ratio compares a company's market value to its book value. A PB ratio significantly higher than the sector average of 2.67 suggests that investors may be overpaying for Joint's stock relative to its underlying assets.
Additionally, Joint's Return on Equity (ROE) Ratio is -47.39, compared to the sector average of -74.11. ROE measures a company's profitability by revealing how much profit it generates with shareholders' equity. While Joint's ROE is less negative than the sector average, it still indicates that the company is not effectively using equity to generate profits.
Furthermore, the company's Return on Assets (ROA) Ratio is -10.66, versus the sector's -47.59. ROA assesses how efficiently a company uses its assets to produce earnings. A negative ROA indicates that Joint is struggling to generate returns from its asset base, although it is performing better than its sector average.
In summary, Joint's elevated PB ratio and negative profitability metrics suggest that the company may be overvalued in the current market, which warrants caution for potential investors.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.